Financials Lushang Freda Pharmaceutical Co.,Ltd.

Equities

600223

CNE000001147

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
8.68 ^CNY	+2.84%		-0.69%	-9.87%

29/04	Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
21/03	Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,438	8,595	13,371	10,765	9,790	8,824	-	-
Enterprise Value (EV) ¹	8,438	8,595	13,371	10,765	9,790	8,824	8,824	8,824
P/E ratio	24.8 x	13.5 x	37.9 x	265 x	32.1 x	23.3 x	18.1 x	15.1 x
Yield	-	-	0.83%	-	1.04%	1.25%	1.54%	1.81%
Capitalization / Revenue	-	0.63 x	1.08 x	0.83 x	2.14 x	1.86 x	1.58 x	1.38 x
EV / Revenue	-	0.63 x	1.08 x	0.83 x	2.14 x	1.86 x	1.58 x	1.38 x
EV / EBITDA	-	8.86 x	17.2 x	24.7 x	17.3 x	14.4 x	11.7 x	9.38 x
EV / FCF	-	-	-	12.9 x	36.7 x	3.58 x	166 x	68.9 x
FCF Yield	-	-	-	7.78%	2.72%	28%	0.6%	1.45%
Price to Book	-	2.7 x	3.49 x	2.9 x	2.44 x	2 x	1.84 x	1.69 x
Nbr of stocks (in thousands)	10,00,968	10,08,831	10,09,152	10,16,569	10,16,569	10,16,569	-	-
Reference price ²	8.430	8.520	13.25	10.59	9.630	8.680	8.680	8.680
Announcement Date	09/04/20	26/03/21	14/04/22	30/03/23	21/03/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	13,615	12,363	12,951	4,579	4,738	5,569	6,381
EBITDA ¹	-	970.1	778.2	435.3	565.3	612.6	753	940.8
EBIT ¹	-	875.4	677.7	310.8	419.4	517.6	667.7	808.2
Operating Margin	-	6.43%	5.48%	2.4%	9.16%	10.92%	11.99%	12.67%
Earnings before Tax (EBT) ¹	-	853.5	643.7	261.1	413	506.6	657.7	796.2
Net income ¹	344.5	638.7	361.9	45.46	303.4	376.8	486.8	585.1
Net margin	-	4.69%	2.93%	0.35%	6.63%	7.95%	8.74%	9.17%
EPS ²	0.3400	0.6300	0.3500	0.0400	0.3000	0.3722	0.4800	0.5750
Free Cash Flow ¹	-	-	-	837.7	266.7	2,467	53	128
FCF margin	-	-	-	6.47%	5.82%	52.07%	0.95%	2.01%
FCF Conversion (EBITDA)	-	-	-	192.42%	47.17%	402.68%	7.04%	13.61%
FCF Conversion (Net income)	-	-	-	1,842.87%	87.9%	654.72%	10.89%	21.88%
Dividend per Share ²	-	-	0.1100	-	0.1000	0.1083	0.1340	0.1575
Announcement Date	09/04/20	26/03/21	14/04/22	30/03/23	21/03/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1
Net sales	-
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	129.3
Net margin	-
EPS	-
Dividend per Share	-
Announcement Date	27/04/23

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	838	267	2,467	53	128
ROE (net income / shareholders' equity)	-	20%	8.34%	1.01%	7.56%	8.58%	10.1%	11.1%
ROA (Net income/ Total Assets)	-	-	-	-	-	4.64%	5.52%	6.64%
Assets ¹	-	-	-	-	-	8,121	8,819	8,815
Book Value Per Share ²	-	3.150	3.790	3.660	3.950	4.340	4.730	5.150
Cash Flow per Share ²	-	4.410	6.790	0.9800	0.4700	1.420	0.5500	1.270
Capex ¹	-	156	281	160	207	209	247	277
Capex / Sales	-	1.15%	2.27%	1.24%	4.53%	4.42%	4.44%	4.33%
Announcement Date	09/04/20	26/03/21	14/04/22	30/03/23	21/03/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lushang Freda Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.68 CNY

Average target price

11.78 CNY

Spread / Average Target

+35.77%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUSHANG FREDA PHARMACEUTICAL CO.,LTD.	-9.87%	118.84Cr
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	59TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+14.25%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals